Article
A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome.
The Journal of biological chemistry - 29 Oct 2004
Tanimoto Yukiho, Yokozeki Masahiko, Hiura Kenji, Matsumoto Kazuya, Nakanishi Hideki, Matsumoto Toshio, Marie Pierre J, Moriyama Keiji
Abstract excerpt
Apert syndrome is an autosomal dominant disease characterized by craniosynostosis and bony syndactyly associated with point mutations (S252W and P253R) in the fibroblast growth factor receptor (FGFR) 2 that cause FGFR2 activation. Here we investigated the role of the S252W mutation of FGFR2 on os...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.